- Policy
- Only Rinvoq to undergo drug pricing reduction
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- As the reimbursement of drug switching between biological agents and JAK inhibitors for the treatment of severe atopic dermatitis will be implemented next month, additional claim amounts are reported to be insignificant. Rinvoq ER Tab (AbbVie, upadacitinib) is the only product to see drug pricing reduction due to the expected additional
- Policy
- Generic drugs enter KRW 150 billion Prolia market
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- A competitor to Prolia (Amgen, co-marketed by Chong Kun Dang), which has dominated the market for osteoporosis treatment with its convenience and efficacy, will be released next month. Celltrion will make the launch. Celltrion plans to launch its biosimilar after the expiration of the Prolia product patent on the 17th of next month. Ac
- Policy
- PMS of Rekovelle shows ovarian hyperstimulation
- by Lee, Hye-Kyung Feb 21, 2025 05:56am
- The reevaluation of Ferring Korea’s fertility drug ‘Rekovelle Prefilled Pen (follitropin delta)’ revealed that 0.65% of patients experienced ovarian hyperstimulation syndrome, which is expected to be added as an adverse event. The Ministry of Food and Drug Safety announced on the 20th the proposed changes to the licensed conditions fol
- Policy
- Ocrevus, DM Duo reimbursed from March
- by Lee, Jeong-Hwan Feb 21, 2025 05:56am
- Roche's new multiple sclerosis drug Ocrevus (ocrelizumab) and Hyundai Pharm’s first dementia combination drug DM Duo (donepezil + memantine) will be reimbursed by Korea’s national health insurance starting next month. Amgen's osteoporosis drug Prolia will see some changes to its reimbursement standard as Celltrion's biosimilar Stoboclo
- Policy
- 'JAK inh-biological agent' switching will be reimb in March
- by Lee, Jeong-Hwan Feb 21, 2025 05:56am
- The National Health Insurance reimbursement standard for severe atopic dermatitis treatments will be extended starting March 1. The key change is reimbursement coverage for switching between JAK inhibitor and biological agent. The Ministry of Health and Welfare (MOHW) announced on February 20 that it gave administrative notice of 'Partial
- Policy
- Pfizer 'Vyndamax' reimbursed from March…KRW 100,000/cap
- by Lee, Tak-Sun Feb 21, 2025 05:56am
- About 20% of the non-reimbursed price…significantly reduces patient with a special exemption of calculation provisions The completion of negotiations with the National Health Insurance Service (NHIS) has been reported, so the reimbursement listing was a matter of time. The ceiling price is reported to be KRW 100,000 per capsule. Accor
- Policy
- Dilemmas for fostering pharma and lowering drug prices
- by Lee, Tak-Sun Feb 19, 2025 05:56am
- What would be a reasonable drug pricing policy to foster new drug development? The government is focusing on the sustainability of the National Health Insurance, while the industry expresses concerns about decreasing new drug development due to reduced drug prices. These conflicting perspectives are raising about the future direction of drug pri
- Policy
- Boehringer Ingelheim, HIRA enter drug price negotiations
- by Lee, Tak-Sun Feb 19, 2025 05:56am
- As for reimbursement listing of 'Ofev (nintedanib),' a treatment for idiopathic pulmonary fibrosis (IPF), domestic distributor Boehringer Ingelheim and the Health Insurance Review and Assessment Service (HIRA) have entered drug price negotiations. Since the substance patent of Ofev expired last month, generic companies have already obtain
- Policy
- Lorviqua, Tevimbra, Pemazyre enter NHIS negotiations
- by Lee, Tak-Sun Feb 18, 2025 05:53am
- Three items, including Lorviqua (lorlatinib, Pfizer Korea), Tevimbra Inj 100 mg (tislelizumab, BeiGene Korea), and Pemazyre (pemigatinib, Handok), are currently under negotiations with the National Health Insurance Service. These drugs were deliberated by the Health Insurance Review and Assessment Service Drug Reimbursement Evaluation Co
- Policy
- Daewoong’s P-CAB Fexuclue completes first PVA
- by Lee, Tak-Sun Feb 17, 2025 05:53am
- Daewoong Pharmaceutical's new drug for gastroesophageal reflux disease, ‘Fexuclue,' has agreed to complete negotiations through the price-volume agreement system with the National Health Insurance Service for the first time since its reimbursement listing. Before negotiations, Daewoong Pharmaceutical was known to have wanted to apply the
